Skip to main content

PCLS, Genesys Partner to Offer Proteomics Lung Cancer Test

NEW YORK (GenomeWeb News) – Physician's Choice Laboratory Services today announced a partnership to offer Genesys Biolabs' proteomic test for screening and the early detection of lung cancer.

The test, called PAULA's Test, short for Protein Assay Using Lung Cancer Analytes, measures three tumor proteins and an additional analyte that are commonly associated with lung cancer. The blood-based test is analyzed in Genesys' CLIA-certified laboratory.

Citing statistics from the American Cancer Society, PCLS said that about 228,190 new cases of lung cancer will be diagnosed this year in the US with 159,480 lung cancer-associated deaths.

PCLS, based in Rock Hill, SC, provides toxicology and genetics testing services. Genesys is a division of 20/20 GeneSystems and develops proteomic-based diagnostics tests with a focus on cancer. It is headquartered in Rockville, Md.

Financial and other terms of the agreement were not disclosed.

The Scan

Response Too Slow, Cautious

A new report criticizes the global response to the threat of the COVID-19 pandemic, Nature News reports.

Pushed a Bit Later

Novavax has pushed back its timeline for filing for authorization for its SARS-CoV-2 vaccine, according to Bloomberg.

AMA Announces Anti-Racism Effort

The Associated Press reports that the American Medical Association has released a plan to address systemic racism in healthcare.

Nucleic Acids Research Papers on miRMaster 2.0, MutationTaster2021, LipidSuite

In Nucleic Acids Research this week: tool to examine small non-coding RNAs, approach to predict ramifications of DNA variants, and more.